Form 4: LeMaitre Vascular CEO Plans Major Stock Sale

LeMaitre Vascular's Chairman and CEO, George W. LeMaitre, plans to sell 100,000 shares of common stock on August 6, 2025, under a pre-arranged 10b5-1 plan.

Summary

• George W. LeMaitre, Chairman and CEO of LeMaitre Vascular Inc. (LMAT), intends to sell 100,000 shares of common stock.
• The transaction is scheduled for August 6, 2025.
• The shares will be sold at a weighted average price of $93.5053 per share, with individual trades ranging from $93.03 to $94.00.
• This sale is being conducted under a Rule 10b5-1(c) plan, which was adopted on March 10, 2025.
• Following this transaction, Mr. LeMaitre will directly own 1,727,003 shares of LeMaitre Vascular common stock.

Sentiment

Score: 4

Explanation: The planned sale of a significant number of shares by the Chairman and CEO, while executed under a pre-arranged 10b5-1 plan (which reduces the implication of immediate negative sentiment), could still be perceived as a neutral to slightly negative signal by some investors. The future date of the transaction also lessens immediate impact.

Negatives

• A significant insider sale of 100,000 shares by the Chairman and CEO, even under a 10b5-1 plan, could be perceived by some investors as a neutral to slightly negative signal regarding future prospects or personal diversification strategies.

Risks

• Potential for minor negative investor sentiment or speculation due to a significant insider stock sale by the Chairman and CEO, despite being pre-planned under a Rule 10b5-1(c) plan.

Future Outlook

The filing indicates a planned sale of 100,000 shares of common stock by the Chairman and CEO on August 6, 2025, under a pre-arranged 10b5-1 plan. This transaction is a personal financial management event and does not provide forward-looking guidance on the company's operational or financial performance.

Industry Context

This Form 4 filing reports a routine insider transaction under a pre-arranged plan, which is a common practice for executives managing their personal holdings. It does not provide information directly related to broader industry trends in the medical device or vascular products sector, nor does it reflect on the company's competitive position within the industry.

Stakeholder Impact

• Shareholders: Potential for minor negative sentiment or increased scrutiny due to a significant insider sale, although the pre-arranged 10b5-1 plan mitigates concerns about opportunistic selling based on undisclosed information.

Next Steps

• Execution of the planned sale of 100,000 shares of common stock by George W. LeMaitre on August 6, 2025.

Key Dates

Keywords

LEMAITRE VASCULAR, LMAT, insider trading, stock sale, Form 4, CEO, George W. LeMaitre, 10b5-1 plan, equity securities